Integer Holdings Corporation Faces Class Action for Securities Fraud After 32% Stock Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Integer Holdings Corporation and its executives for securities fraud following a significant stock drop, with investors encouraged to apply to lead the case by February 9, 2026.
- Performance Decline: On October 23, 2025, Integer lowered its sales guidance to between $1.840 billion and $1.854 billion, well below analyst expectations, causing its stock price to plummet from $109.11 to $73.89, a decline of over 32%.
- False Market Demand Claims: The company had repeatedly overstated the demand for its electrophysiology devices, while actual sales had sharply declined, directly contradicting its public assurances and undermining investor confidence.
- Pessimistic Future Outlook: Integer anticipates net sales growth of -2% to 2% for 2026 and admitted that two of its EP devices are experiencing slower-than-expected adoption, indicating that weak demand may persist, further eroding shareholder confidence.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 78.430
Low
69.00
Averages
91.75
High
140.00
Current: 78.430
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
